Specialty pharmaceutical firm Akorn (AKRX) finishes the day up over 10% after its Q3 easily...

|By:, SA News Editor

Specialty pharmaceutical firm Akorn (AKRX) finishes the day up over 10% after its Q3 easily beats estimates. Revenue jumped 69% Y/Y on higher sales and the continued growth of its injectable and ophthalmic products launched in 2010. Gross margin rose to 60% due to a favorable product mix, price increases and more efficient plant utilization.